Oragenics partners Receptor.AI for brain health candidate portfolio
Clinical-stage biotechnology company Oragenics has announced a strategic collaboration with the US-based tech bio firm Receptor.AI to expedite the development…
Central Nervous System
-
-
FDA lifts clinical hold on Neurizon’s ALS drug
The US Food and Drug Administration (FDA) has released its clinical hold on Neurizon Therapeutics’ NUZ‑001, paving the way for…
-
NMPA approves Eisai and Biogen for Leqembi IV maintenance dosing
China's National Medical Products Administration (NMPA) has granted approval for four-weekly intravenous (IV) maintenance dosing of Eisai and Biogen’s Leqembi…
-
Roche bids to broaden MS pipeline and strengthen Ocrevus influence
Roche plans to present data at a major multiple sclerosis (MS) conference indicating the continued efficacy of its investigational Bruton…
-
FDA delays approval decision for Sanofi’s MS treatment tolebrutinib
There’s been another detour in tolebrutinib’s path to market, with developer Sanofi revealing that the US Food and Drug Administration…
-
Reunion Neuroscience expands Series A to $133m after positive trial milestones
The success of Reunion Neuroscience’s lead psychedelic candidate in a postpartum depression (PPD) trial has provided a last minute boost…
-
Novartis returns to alpha-synuclein with $2.2bn Arrowhead deal
Novartis is returning to the alpha-synuclein protein as a possible treatment for Parkinson’s disease, signing a licensing deal worth up to…
-
Eisai’s Leqembi unlocks at-home dosing with FDA autoinjector approval
The US Food and Drug Administration (FDA) has approved a once-weekly autoinjector version of Eisai’s Alzheimer’s drug Leqembi (lecanemab), as…
-
Amylyx culls rare neurological disorder programme after trial failure
Amylyx Pharmaceuticals has discontinued a clinical programme evaluating a neuronal cell death inhibitor as a result of disappointing data when tested…
-
Apertura signs multiple licensing agreements for TfR1 CapX tech
Apertura Gene Therapy has entered several licensing agreements to advance central nervous system (CNS) treatments using its transferrin receptor 1…
